Table III. Response data by disease site and histology.
| Disease site histology |
patients treated # |
CR N (%) |
PR N (%) |
SD ≥ 6 months N (%) |
CR+PR+SD ≥ 6 months N (%) |
Median # cycles completed (range) |
|---|---|---|---|---|---|---|
| Uterus | 21 | 5 (1-20) | ||||
| Epithelial | 18 | 5 (27.8) | 4 (22.2) | 9 (50) | 6 (1-20) | |
| Leiomyosarcoma | 3 | 1 (0-2) | ||||
| Ovary | 20 | 4 (2-13) | ||||
| Epithelial (high grade) | 16 | 3 (18.8) | 4 (25) | 7 (43.8) | 6 (1-13) | |
| Epithelial (low grade) | 1 | |||||
| Granulosa | 2 | 4 (1-8) | ||||
| Sarcoma | 1 | 2 | ||||
| Cervix | π 13 | 3 (1-7) | ||||
| Squamous | 10 | 2 (15.4) | 1 (7.7) | 3 (23.1) | 3 (1-6) | |
| Adenocarcinoma | 3 | 2 (1-7) | ||||
| Breast | π 20 | 5 (1-12) | ||||
| Ductal | 11 | 1 (5) | 1 (5) | 2 (10) | 3 (15) | 4 (1-8) |
| Lobular | 1 | 1 (5) | 1 (5) | 2 (10) | 9 (7–12) | |
| Metaplastic | 8 | 2 (10) | 1 (5) | 4 (20) | 5 (4-8) |
ξ
prolonged SD defined as trial enrollment for more than or equal to 180 days
π
Organ specific histologic subtypes grouped to determine denominator